Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM EDTCredit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).
Analyst Vamil Divan said as they look ahead they believe there are still no signs of stabilization for some of the key issues impacting TEVAs core... More
Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%
August 3, 2017 11:17 AM EDTTeva Pharma (NYSE: TEVA) Cracks Fresh Low, Now Down 19.65%
... MoreTeva Pharma (TEVA) Sinks 16% on Weak Results, Outlook
August 3, 2017 8:18 AM EDTTeva Pharma (NYSE: TEVA) shares sink nearly 16% in pre-open trade following weak results and outlook.
... MoreTeva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend
August 3, 2017 6:33 AM EDT(Updated - August 3, 2017 6:40 AM EDT)
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.02, $0.04 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.76 billion.
GUIDANCE:
Teva Pharma sees Q3 2017 EPS of $4.30-$4.50, versus the consensus of $4.74.
We... More